webinar register page

Webinar banner
Enzo Webinar: Clinical applications for epigenetic biomarkers | Prof. Dr. T.K. Wojdacz
In general terms, malfunctioning of epigenetic mechanisms regulating gene expression leads to diseases such as neoplastic transformation. Biomarker assays targeting disease related epigenetic changes can effectively be utilized as biomarkers at all stages of clinical disease management, from risk assessment, through early diagnosis and treatment personalization, to post treatment surveillance. Recently, large-scale clinical trials have shown that methylation biomarker-based cancer detection in liquid biopsies allows early detection of cancer in patients with remarkable specificity and sensitivity Specifically, detection of BRCA1 gene methylation in blood has been proposed as a biomarker of predisposition to breast and ovarian cancers. Additionally, methylation of the MGMT gene has long been used to guide treatment of glioblastoma multiforme patients. And recently, the genome wide profiling methylation has been suggested by the WHO as an alternative to standard histopathology for the classification of brain tumors. In my talk I will review recent developments in methylation biomarker research and applications of epigenetic biomarkers in clinical disease management.

Apr 19, 2023 04:00 PM in Paris

Webinar logo
* Required information


Prof. Dr. Tomasz K. Wojdacz
Associate Professor @Department of Biomedicine, Aarhus University, Denmark
Dr Tomasz K Wojdacz received PhD in Medicine from the faculty of Health Sciences, Aarhus University, Denmark. He is currently an associate professor of Personalized Medicine at Aarhus University, Denmark and leads a research team at Pomeranian Medical University in Szczecin, Poland. He has been conducting research in internationally recognized institutions such as the Peter MacCallum Cancer Centre, Melbourne, Australia; the Institute of Biomedicine, Aarhus, Denmark; the Karolinska Institute, Stockholm, Sweden; and Southampton University, UK. He was also Maria Skłodowska-Curie fellow at the Aarhus Institute of Advanced Studies, Denmark. Dr. Wojdacz main interest is translational cancer research, with a focus on clinical epigenetics and personalized medicine. He successfully commercialized the EpiMelt technology that he developed, which now is entering diagnostic laboratories worldwide.